Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: A mediation analysis

Journal of Clinical Psychopharmacology

Volumn 29, Issue 5, 2009, Pages 496-497

  Hough, David ^a   Nuamah, Isaac F ^a   Lim, Pilar ^a   Sampson, Allan ^b   Gagnon, Dennis D ^a   Rothman, Margaret ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIPERIDONE; PLACEBO;

DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LETTER; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL INTERACTION;

ADULT; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; NEGOTIATING; PYRIMIDINES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SOCIAL BEHAVIOR;

EID: 70349680401     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181b5f40b     Document Type: Letter

References (11)

1. Wheeler Vega JA, Mortimer AM, Tyson PJ. Somatic treatment of psychotic depression: review and recommendations for practice. J Clin Psychopharmacol. 2000;20:504-519.
2. Schatzberg AF, Rothschild AJ. Psychotic (delusional) depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry. 1992;149:733-745.
3. Bruijn JA, Moleman P, Mulder PG, et al. Treatment of mood-congruent psychotic depression with imipramine. J Affect Disord. 2001;66:165-174.
4. Wijkstra J, Burger H, van den Broek WV, et al. Treatment of unipolar psychotic depression. A randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatr Scand. In Press.
5. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23: 56-62.
6. Bertschy G, RagamaPardos E, Ait-Ameur A, et al. Lithium augmentation in venlafaxine non-responders: An open study. Eur Psychiatry. 2003;18:314-317.
7. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders. Dutch Translation. Lisse, The Netherlands: Swets & Zeitlinger; 1999.
8. Bruijn JA, Moleman P, Mulder PG, et al. Comparison of 2 treatment strategies for depressed inpatients: imipramine and lithium addition or mirtazapine and lithium addition. J Clin Psychiatry. 1998;59:657-663.
9. Birkenhäger TK, van den Broek WW, Mulder PG, et al. Comparison of two-phase treatment with imipramine or fluvoxamine, both followed by lithium addition, in inpatients with major depressive disorder. Am J Psychiatry. 2004;161:2060-2065.
10. Bauer M, Bschor T, Kunz D, et al. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry. 2000;157:1429-1435.
11. Bschor T, Berghofer A, Strohle A, et al. How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol. 2002;22:427-430.